Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00869050 · ClinicalTrials.gov registry record · Phase 2
Capecitabine and Temozolomide for Neuroendocrine Cancers
A Phase 2 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00869050 is a Phase 2 study that has completed, run by Columbia University. The registered enrollment target is 41 participants.
The verdict
NCT00869050, a Phase 2 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This phase II study is designed to assess whether treatment with capecitabine/temozolomide (CAP/TEM) is safe and effective in treating subjects with progressive, differentiated, metastatic neuroendocrine tumors (NET). The primary objective of the study is to determine the radiologic response rate to this regimen in progressive, metastatic, differentiated neuroendocrine cancers.
Interventions
- DRUG Capecitabine
- DRUG Temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2005-08 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00869050
The ClinicalTrials.gov registry entry for NCT00869050 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capecitabine is the first listed.
NCT00869050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00869050 about?
NCT00869050 is a clinical study titled "Capecitabine and Temozolomide for Neuroendocrine Cancers". This phase II study is designed to assess whether treatment with capecitabine/temozolomide (CAP/TEM) is safe and effective in treating subjects with progressive, differentiated, metastatic neuroendocrine tumors (NET). The primary objective of the study is to determine the radiologic response rate to...
What is the current status of trial NCT00869050?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2005-08. Estimated completion is 2014-10.
What interventions are being tested in trial NCT00869050?
The interventions under investigation include: Capecitabine (DRUG), Temozolomide (DRUG).
Who is sponsoring clinical trial NCT00869050?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.